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Abstract
Substrains of the Spontaneously Hypertensive rat (SHR), a putative animal model of Attention-Deficit/Hyperactivity
Disorder (ADHD), have demonstrated increased sensitivity to many drugs of abuse, including psychostimulants.
Therefore, it was suggested that studies in SHR may help elucidate ADHD and comorbidity with substance use dis-
order (SUD). However, the drug intake profile of the SHR in the most relevant animal model of drug addiction, the
self-administration (SA) test, and its response on the conditioned place preference (CPP) paradigm are not yet
determined. In the present study, we employed SA and CPP tests to investigate the reinforcing effects of the psy-
chostimulant methamphetamine in an SHR substrain obtained from Charles River, Japan (SHR/NCrlCrlj). Concurrent
tests were also performed in Wistar rats, the strain representing “normal” heterogeneous population. To address if
the presence of ADHD behaviors further increases sensitivity to the rewarding effect of methamphetamine during
adolescence, a critical period for the onset of drug abuse, CPP tests were especially conducted in adolescent Wistar
and SHR/NCrlCrlj. We found that the SHR/NCrlCrlj also acquired methamphetamine SA and CPP, indicating reinfor-
cing effects of methamphetamine in this ADHD animal model. However, we did not observe increased responsive-
ness of the SHR/NCrlCrlj to methamphetamine in both SA and CPP assays. This indicates that the reinforcing
effects of methamphetamine may be similar in strains and that the SHR/NCrlCrlj may not adequately model ADHD
and increased sensitivity to methamphetamine.
Findings
Attention-Deficit/Hyperactivity Disorder (ADHD) is a
complex neurodevelopmental disorder characterized by
the core symptoms such as hyperactivity, inattention
and impulsivity [1,2]. It is the most commonly diag-
nosed disorder of childhood [3] and also present in
about 4%-9% of youths [4,5] and 4% of adults [6].
ADHD is comorbid with substance use disorder (SUD)
[7,8] and epidemiological data not only affirm the
ADHD-SUD link but also indicate greater risk for earlier
onset of substance abuse among ADHD individuals
[4,9-11]. The exact etiology, however, cannot be deter-
mined for in some respects, there is a lack of appropri-
ate animal models [12].
The Spontaneously Hypertensive rat (SHR), bred from
the normotensive Wistar Kyoto (WKY) rat strain, is the
most validated animal model of ADHD [13]. A number
of SHR substrains exist [14] and Sagvolden et al [15]
asserted that the SHR obtained from Charles River,
Germany (SHR/NCrl), with the WKY bred from Harlan,
UK (WKY/NHsd) as the reference strain, most excel-
lently represents ADHD. Nevertheless, earlier studies
have found increased reactivity of some SHR substrains
(e.g. SHR/NTac, SHR/NCrl) to stimulants, opioids, alco-
hol and other addictive drugs in comparison with other
rat strains [see [12] for review], indicating that the SHR,
i ng e n e r a l ,m a yb eu s e dt oi n v e s t i g a t et h er e l a t i o n s h i p
between ADHD and drug addiction. However, the beha-
vioral profiles of the SHR in the most relevant drug
addiction assay, the self-administration (SA) paradigm
[12] and in another animal model of addiction, the con-
ditioned place preference (CPP) protocol [16] are not
completely known.
In this study, we conducted SA and CPP tests in an
SHR substrain obtained from Charles River, Japan
(SHR/NCrlCrlj) (via Orient Bio., Korea), to investigate if
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phetamine. Its response was compared with the Wistar
rat, strain representing the “normal” heterogeneous
population [17-19]. Adolescence is a risk factor for
addiction [20] and it is known that children with ADHD
are more vulnerable to use illicit drugs than children
without it [21,22]. We would like to know if we can
model this in our study, thus CPP tests were conducted
in adolescent Wistar and SHR/NCrlCrlj.
All experiments complied with the Principles of
Laboratory Animal Care (NIH) and the Animal Care
and Use Guidelines of Sahmyook University, Korea. We
used adolescent (PND 20-47) and adult (PND 90-110)
male outbred Wistar and inbred SHR/NCrlCrlj. They
were housed collectively (8 rats/cage in CPP experi-
ments) or individually (SA experiments), in a tempera-
ture (22 ± 2°C) and humidity- (55 ± 5%) controlled
animal room with a 12 hr/12 hr light/dark (6 AM-6
PM) cycle. They had free food and water access except
during tests and on initial lever-training sessions (SA
test). Methamphetamine hydrochloride, procured from
Korea Food and Drug Administration, was dissolved in
saline for use in all experiments.
Self-administration tests were carried out in standard
operant chambers (Coulbourn Instruments, Allentown,
PA, USA) and the methods employed were as outlined
previously [23]. Briefly, after rats acquired stable lever
responding, they were implanted with silastic catheters
in the right jugular vein. SA tests commenced after they
have recovered from surgery. Two levers were present
during SA tests and response on the left lever (active
lever, FR1) switched on the infusion pump for 10 s,
delivering 0.1 ml of 0.25 mg methamphetamine, and
also the stimulus light above it (which was lit for 10 s
and 20 s more after the end of the infusion). A time-
out period was indicated and no priming injections
were given at any time. Rats were only allowed up to 30
infusions although lever responses were recorded until
the end of the 2-hour SA. Catheter patency was ensured
as detailed [23].
Conditioned place preference tests were conducted in
two-compartment polyvinylchloride boxes having dis-
tinct visual and tactile cues. The methods were pat-
terned after previous reports [23,24] with some
modifications. After determining the rats’ initially-pre-
ferred compartment, approximately half of the rats per
group were assigned to the black compartment as the
drug-paired side, while the other half to the other [24].
If their staying time was less than 200 s, they were
excluded from further testing. Conditioning phase fol-
lowed where animals were paired with methampheta-
mine (1.25 or 5 mg/kg) or saline in their non-preferred
Figure 1 Acquisition of methamphetamine self-administration (SA). (A) Mean total number of lever responses of Wistar rats and SHR/
NCrlCrlj during the 2-hour methamphetamine SA. Open symbols indicate lever responses on the active (reinforced) lever and filled symbols
show responses for the inactive (non-reinforced) lever. (B) Mean infusions obtained by Wistar and SHR/NCrlCrlj during the 2-hour
methamphetamine self-administration. Empty squares are responses of Wistar rats and circles are for SHR/NCrlCrlj. Data are presented as means
± SEM (n = 6).
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formed as described [23]. Post- and preconditioning
staying times were determined using automated systems
(Ethovision Noldus IT b.v., Netherlands).
Two-way ANOVA was used to determine the effects
of strains or days or interaction between these factors in
SA tests (active vs inactive lever presses, and total num-
ber of methamphetamine infusions) and also in CPP
t e s t s( s t r a i n so rt r e a t m e n te f f e c t sa n di n t e r a c t i o n
between them). Student’s t-test was used for further
analysis. The significance level was set to p < 0.05.
Figure 1A shows that both strains acquired metham-
phetamine SA. Responses for the active vs inactive lever
differed significantly in Wistar (F (1,50) = 59.92, p <
0.001) and in SHR/NCrlCrlj (F (1,50) = 42.26, p <
0.001). However, two-way ANOVA only revealed signifi-
cant effect of days (F (4,50) = 5.69, p < 0.001), but with-
out any strain × days interaction. In Figure 1B, the
number of methamphetamine infusions earned by SHR/
NCrlCrlj and Wistar rats during the SA tests is shown.
Significant days (F (4,50) = 7.01, p < 0.001) but not
strain effects was noted, and there was no strain x days
interaction.
Figure 2 illustrates that CPP was expressed by both
strains in response to methamphetamine conditioning.
There was a remarkable effect of treatment (F (2,42) =
6.46, p < 0.05), but no strain effects, and strain × treat-
ment interaction. In Wistar rats, there was CPP
to 1.25 mg/kg (t (14) = 1.81, p < 0.05) and 5 mg/kg
(t (14) = 2.17, p < 0.05) methamphetamine. CPP was
also demonstrated by SHR/NCrlCrlj conditioned with
1.25 (t (14) = 3.33, p < 0.01) and 5 mg/kg (t (14) = 2.96,
p < 0.01) methamphetamine.
This study showed that the SHR/NCrlCrlj, alike
the Wistar rat, readily acquired methamphetamine self-
administration. Adolescent SHR/NCrlCrlj also demon-
strated conditioned place preference to methampheta-
mine although in both assays differential strain response
Figure 2 Rewarding effects of methamphetamine (METH) in Wistar and SHR/NCrlCrlj. (A) Place preference data (mean ± SEM) expressed as
the difference in the amount of time spent in the METH-paired compartment during the post- and preconditioning days. Data are expressed as
mean ± SEM. *p < 0.05, **p < 0.01 when comparing saline (SAL) vs METH-conditioned animals (n = 8).
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rewarding properties of methamphetamine are similar in
both strains and more importantly, that the SHR/
NCrlCrlj may not be more sensitive to methampheta-
mine reward/reinforcement. The results herein do not
conform to previous investigations. Initially, it has been
predicted that the SHR would show increased behavioral
response to addictive drugs not only for their ADHD-
like behaviors, but also as it manifests high levels of
impulsivity, novelty-seeking behaviors [25] and defec-
tive/deficient reinforcement processes [26]. These beha-
viors predispose greater vulnerability to drug abuse as
known in human studies [27,28]. Secondly, our results
do not coincide with previous studies (which used loco-
motor activity as an index to the reinforcing effects of
drugs) which demonstrated increased behavioral
response of an SHR substrain (SHR/NTac) to ampheta-
mine, methylphenidate and the selective D1 receptor
agonist SKF-81297, as compared to Wistar Kyoto rats
(WKY/NTac) [29-32]. However, one study has found
similarity of the effects of amphetamine or GBR-12909,
ad o p a m i n er e u p t a k ei n h i b i t o r ,i na n o t h e rS H Rs u b -
strain (SHR/Cbp) and in WKY/Cbp [33]. The present
inconsistency could be due tot h ef o l l o w i n gf a c t o r s :
(1) difference in procedures (i.e. locomotor activity and
SA tests measure different aspects of reinforcement
mechanism) and (2) difference in SHR substrains used
(i.e. the SHR substrain used herein may deviate phenoty-
pically or genetically from SHR/NCrl bred in the USA
or elsewhere) [15]. Nevertheless, it has to be considered
that stimulants act differently in exerting their reinfor-
cing effects [34]. This factor may also have influenced
the present results. At any rate, additional investigations
should be performed to resolve this discrepancy.
Our CPP results do not model increased vulnerability
of ADHD children to drugs of abuse in comparison
with “normal” children [21,22]. However, our data may
represent a previous study which showed no difference
in the rates of drug abuse or dependence to individual
substances in both ADHD and non-ADHD controls
[35]. Of interest is that our CPP data agree with those
obtained in SA test. This is notable considering that
CPP and SA are believed to be dissimilar forms of drug
reward [36-38].
In summary, we have shown that the SHR/NCrlCrlj
also shows stable responding and CPP to methampheta-
mine. However, we have not observed increased sensi-
tivity of this substrain to methamphetamine reward/
reinforcement relative to Wistar rats, showing that it
may not fully represent ADHD and increased vulnerabil-
ity to methamphetamine. Concerning methampheta-
mine-induced CPP in SHR/NCrlCrlj, it cannot be
attributed to an anxiolytic effect of repeated metham-
phetamine treatment [see [39]], as drug-induced
anxiolysis (which may influence place preference) is not
always apparent with drug-induced decreases in central
serotonin [40]. It could not be due to “response to
novelty” [36] as the CPP procedure was modified to
minimize the effect of this confound. In future studies,
i tw o u l db ew o r t h w h i l et oc o m p a r et h eb e h a v i o r a l
responses of the SHR/NCrlCrlj or SHR/NCrl (of Charles
River, Germany) with its most appropriate control
strain, the WKY/NHsd, in both SA and CPP assays.
Such work may not only determine the reliability of the
present conclusion, but may also give clues on the con-
tribution of neurobiological differences (seen in ADHD
and non-ADHD individuals) in response to the reinfor-
cing effects of drugs of abuse.
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